Join to View Full Profile
9200 W Wisconsin Ave# ClccMilwaukee, WI 53226
Phone+1 414-805-0509
Fax+1 414-805-6808
Dr. Nelson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 2013 - 2016
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2013
Certifications & Licensure
WI State Medical License 2014 - 2025
OH State Medical License 2016 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 3 citationsOutcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.Matthew M Mirsky, Carley Mitchell, Augustine Hong, Shufen Cao, Pingfu Fu
Cancer Management and Research. 2023-01-01 - 10 citationsMinding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.Anne E Kim, Ariel Nelson, Kyle Stimpert, Rebecca L Flyckt, Nannan Thirumavalavan
JCO Oncology Practice. 2022-12-01 - 7 citationsAssociation of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey
Clinical Genitourinary Cancer. 2022-12-01
Lectures
- Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC).2019 ASCO Annual Meeting - 6/1/2019
- Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.2019 ASCO Annual Meeting - 6/1/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
